^
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
orelabrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
zanubrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
temsirolimus
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
ibrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
rituximab + bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
acalabrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
avapritinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
venetoclax + ibrutinib
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
rituximab
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
bendamustine
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
venetoclax
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
rituximab + ibrutinib + lenalidomide
Sensitive
:
A2
ALK negative
Mantle Cell Lymphoma
brentuximab vedotin
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
VR-CAP
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
R-DHAP
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
R-DHAX
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
R-CVAD
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
R-GemOx
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
venetoclax + rituximab
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
R-CHOP
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive
:
A2
CCR7 positive
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive
:
B
ABCB1 mutation + VEGFA mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive
:
B
VEGFA mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive
:
B
ABCB1 mutation
Mantle Cell Lymphoma
lenalidomide
Sensitive
:
B
No biomarker
Mantle Cell Lymphoma
INCB50465
Sensitive
:
B
CCND1 overexpression
Mantle Cell Lymphoma
INCB50465
Sensitive
:
C2
TP53 mutation
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive
:
C2